Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Comment by Dividendspayon Apr 16, 2019 3:40am
105 Views
Post# 29631534

RE:RE:Weighing in on SP

RE:RE:Weighing in on SPHi F,
I am not making a final judgement about PoNs and whether it is effective or not.
All my comments are meant to relate to the clinical trial and interpretation of it.
To me this is the point.
There may be substantial supporting data that demonstrate efficacy and benefit of PoNs, but that is separate and independent from the rigorous and strict interpretation of the study. 
I referred to this in the thread in the part on conflating results.
Understanding how scientists interpret results is essential to predicting the FDA decision.
The result becomes less surprising then, notwithstanding all the other data many here have made
Maybe PONS is a game changer, maybe it will help many people

This is not what ai was addressing, here, and I hope this makes sense

Anyway,  I really don’t post much, because again, I do not find it to be a great use of my time, but I did with the Original post when I was reading the comments and interpretation of the study which I felt  to be incorrect. 
 I really do think there is important lesson to be learned from this discussion. 
 At the end of the day, I really am sorry for folks that lost money, and for patients that are afflicted with these diseases.
I only wish people well(including Prokiev) and my time on this board was in the spirit of objective analysis of the data, and through discussion, an attempt to clarify the meaning, and improve our abilities of investors(including me as articulating this makes you organize your thoughts)
This thinking led me away from an investment and keeps me on the sidelines
As a result, I really am leaving the discussion as I have little to offer.
I wish everyone well, and wish you all well with your investing.
Good luck everyone, and I wish you the best.




Bullboard Posts